Peer review reports
From: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
| Original Submission |
| 8 Feb 2018 |
Submitted |
Original manuscript
|
| 13 May 2018 |
Author responded |
Author comments - Lilian SCHWARZ
|
| Resubmission - Version 2 |
| 13 May 2018 |
Submitted |
Manuscript version 2
|
| Publishing |
| 5 Jul 2018 |
Editorially accepted |
|
| 24 Jul 2018 |
Article published |
10.1186/s12885-018-4663-4
|
Learn about peer review
